ANI Pharmaceuticals Inc (ANIP)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

210 MAIN STREET WEST BAUDETTE, MN 56623

BioSante Pharmaceuticals is a pharmaceutical company focused on developing products for female sexual health and oncology. Co.'s products for female sexual health, menopause, contraception and male hypogonadi® include its gel formulations of estradiol or testosterone and combinations of estrogen, progestogen and androgen. Co.'s products, either approved or in human clinical development, include LibiGel, a once daily transdermal testosterone gel; a male testosterone gel; GVAX cancer vaccines; the Pill-Plus, a once daily use of various combinations of estrogens, progestogens and androgens; as well as Elestrin, a once daily transdermal estradiol (estrogen) gel.

Data based on most recent fiscal year report
Market Cap735.072 Million Shares Outstanding12.09 Million Avg Volume176.813 Thousand
1-Yr BETA vs S&P TR0.782 Current Ratio0.92 Quick Ratio0.68
View SEC Filings from ANIP instead.

View recent insider trading info

Funds Holding ANIP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ANIP BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

WALSH PATRICK D

  • Director
0 2020-01-09 1

MERIDIAN VENTURE PARTNERS II LP

MERIDIAN VENTURE PARTNERS II GP, L.P.

MERIDIAN VENTURE PARTNERS II, CO.

BROWN ROBERT E. JR

  • Director
  • 10% Owner
2,281,283 2019-08-19 4

SULLIVAN LOUIS W

  • Director
5,120 2019-06-26 0

SHERWIN STEPHEN A

  • Director
0 2019-06-25 0

DONENBERG PHILLIP B.

  • Director
0 2019-06-11 0

NASH DAVID

  • Director
5,236 2019-05-24 2

MARKEN JAMES G. SVP OPS & PROD DEV

  • Officer
61,230 2019-05-17 6

BROWN ROBERT E. JR

  • Director
22,561 2019-05-16 2

HAUGHEY THOMAS

  • Director
6,291 2019-05-15 2

SCHREPFER ROBERT W SVP - NEW BUS DEV & SPEC SALES

  • Officer
55,927 2019-05-13 6

PRZYBYL ARTHUR PRESIDENT AND CEO

  • Officer
  • Director
202,589 2019-05-13 5

CAREY STEPHEN P. VICE PRESIDENT AND CFO

  • Officer
25,450 2019-04-06 3

PENN THOMAS A.

  • Director
14,301 2019-03-28 1

MARSHBANKS TRACY

  • Director
349,934 2018-05-14 0

HOLUBOW FRED

  • Director
14,811 2018-03-20 0

RAYNOR DANIEL

  • Director
289,003 2018-03-15 0

POTTS JOHN T JR

  • Director
159,253 2017-06-09 0

ARNOLD CHARLOTTE C. VICE PRESIDENT AND CFO

  • Officer
54,298 2016-04-07 0

LANKAU PETER A

  • Director
2,500 2016-04-07 0

MANGANO ROSS J

  • Director
26,914 2014-09-15 0

SIMES STEPHEN M CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2014-07-24 0

JAMNICK ROBERT J. VP, QUALITY & PRODUCT DEVELOP.

  • Officer
48,118 2014-05-22 0

BROWN ROBERT E. JR

PENN THOMAS A.

  • Director
  • 10% Owner
16,918,469 2013-06-19 0

MERIDIAN VENTURE PARTNERS II LP

MERIDIAN VENTURE PARTNERS II GP, L.P.

MERIDIAN VENTURE PARTNERS II, CO.

  • 10% Owner
16,918,469 2013-06-19 0

ROSENOW EDWARD C III

  • Director
20,540 2012-03-30 0

SNABES MICHAEL C SR. VP OF MEDICAL AFFAIRS

  • Officer
0 2012-01-25 0

KJAER PETER

  • Director
34,425 2010-03-31 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Click here to report any possible errors with this stock listing.

Elevate your investments